Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Natural Derivatives of Selective HDAC8 Inhibitors with Potent <i>in Vivo</i> Antitumor Efficacy against Breast Cancer by Xiaoming Chen (230202)

“…XZB108, selectively inhibited HDAC8 (IC₅₀ = 0.90 ± 0.014 μM), suggesting that it may be a promising nonhydroxamate HDAC8 inhibitor. …”

Maintenance of weight loss or stability in subjects with obesity: a retrospective longitudinal analysis of a real-world population by Maral DerSarkissian (504144)

“…</p> <p><b>Methods:</b> A retrospective observational longitudinal study of subjects with obesity was conducted using the General Electric Centricity electronic medical record database. …”

Levels of netrin-1, DCC, arginase, NO and ROS in endothelial cells. by Haroldo A. Toque (447341)

Targeting Tyrosinase: Development and Structural Insights of Novel Inhibitors Bearing Arylpiperidine and Arylpiperazine Fragments by Stefania Ferro (76724)

“…The inhibition of tyrosinase (Ty, EC 1.14.18.1) represents an efficient strategy of decreasing melanogenesis and skin hyperpigmentation. …”

Selective Peptidomimetic Inhibitors of NTMT1/2: Rational Design, Synthesis, Characterization, and Crystallographic Studies by Brianna D. Mackie (9212677)

“…Its cell-permeable analogue <b>DC432</b> (IC₅₀ of 54 ± 4 nM) decreases the N-terminal methylation level of the regulator of chromosome condensation 1 and SET proteins in HCT116 cells. …”

Notch signaling regulates the responses of lipopolysaccharide-stimulated macrophages in the presence of immune complexes by Wipawee Wongchana (5367968)

“…A similar impact on IL-10 production was observed when Notch signaling was inhibited with a gamma-secretase inhibitor (GSI). …”

Effects of GSI treatment on MAPK, PI3K/AKT and NF-κB pathway activation in LPS/IC-activated macrophages. by Wipawee Wongchana (5367968)

“…The arrows indicate cells with decreased or no p50 nuclear translocation (green). …”

Phase Behavior and Self-Assembly of Semiflexible Polymers in Poor-Solvent Solutions by Tobia Arcangeli (19540447)

Image_5_Iron Overload in Patients With Heavily Transfused Sickle Cell Disease—Correlation of Serum Ferritin With Cardiac T2* MRI (CMRTools), Liver T2* MRI, and R2-MRI (Ferriscan®).... by Salam Alkindi (11601856)

“…In this evaluable cohort of 44 patients, the mean SF (±SD) reduced marginally from 4,311 to 4,230 ng/ml, mean Liver T2^* MRI dropped from 12 to 10.3 mg/gm dry weight, while the mean cardiac T2^*MRI improved from 36.8 to 39.5 ms. …”

CgA silencing, processing enzyme inhibition and functional analysis of CgA peptides in SI-NEN cell lines. by Francesco Giovinazzo (487256)

“…Inhibition of the CgA processing enzyme prohormone convertase using Decanoyl-Arg-Val-Lys-Arg-CMK also decreased proliferation of H-STS cells (25 µM [<i>data not shown</i>] and 50 µM, <b>4D</b>, *<i>p</i><0.05). …”